Condition: Glioblastoma (GBM) · Glioblastoma - Category · Sponsor: Insel Gruppe AG, University Hospital Bern
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
This description comes directly from the study's public registry record.
Philippe Schucht, MD · +41 31 632 00 14 · philippe.schucht@insel.ch
Alexis P. R. Terrapon, MD · +41 31 66 4 02 39 · alexis.terrapon@insel.ch
Always discuss trial participation with your own doctor first.
| Dep. of Neurosurgery, Bern University Hospital | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07616986